Literature DB >> 11355961

Clinical practice guidelines in cancer: the European perspective.

G Storme1.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11355961      PMCID： PMC2408837          DOI： 10.1054/bjoc.2000.1773

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  7 in total

Review 1.  Outcomes research in oncology: history, conceptual framework, and trends in the literature.

Authors:  S J Lee; C C Earle; J C Weeks
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Biomedical ethics. Penn report, agency heads home in on clinical research.

Authors:  E Marshall
Journal:  Science       Date:  2000-06-02       Impact factor: 47.728

3.  Variations in survival from breast cancer in Europe by age and country, 1978-1989. EUROCARE Working Group.

Authors:  M J Quinn; C Martinez-Garcia; F Berrino
Journal:  Eur J Cancer       Date:  1998-12       Impact factor: 9.162

4.  Survival of cancer patients in Finland 1955-1994.

Authors:  P W Dickman; T Hakulinen; T Luostarinen; E Pukkala; R Sankila; B Söderman; L Teppo
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

5.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

6.  The promise and problems of meta-analysis.

Authors:  J C Bailar
Journal:  N Engl J Med       Date:  1997-08-21       Impact factor: 91.245

7.  Discrepancies between meta-analyses and subsequent large randomized, controlled trials.

Authors:  J LeLorier; G Grégoire; A Benhaddad; J Lapierre; F Derderian
Journal:  N Engl J Med       Date:  1997-08-21       Impact factor: 91.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.